Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm multicenter study of TQ-B3525 in relapsed or refractory follicular lymphoma
CTR20200426Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQ-B3525 in follicular lymphoma (FL), mature B-cell lymphoma, nodal marginal zone B-cell lymphoma (NMZL), extranodal marginal zone B-cell lymphoma (EMZL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started May 2020; status: active.
02
Drugs
TQ-B3525
03
Conditions
follicular lymphoma (FL)mature B-cell lymphomanodal marginal zone B-cell lymphoma (NMZL)extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on CTR20200426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200426.